VESICARE LS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vesicare Ls, and what generic alternatives are available?
Vesicare Ls is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
The generic ingredient in VESICARE LS is solifenacin succinate. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vesicare Ls
A generic version of VESICARE LS was approved as solifenacin succinate by TEVA PHARMS USA on April 2nd, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VESICARE LS?
- What are the global sales for VESICARE LS?
- What is Average Wholesale Price for VESICARE LS?
Summary for VESICARE LS
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 67 |
| Patent Applications: | 2,287 |
| Drug Prices: | Drug price information for VESICARE LS |
| DailyMed Link: | VESICARE LS at DailyMed |
Recent Clinical Trials for VESICARE LS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Genuine Research Center, Egypt | Phase 1 |
| Hikma Pharma | Phase 1 |
| Brigitte Schürch | Phase 4 |
Paragraph IV (Patent) Challenges for VESICARE LS
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VESICARE LS | Oral Suspension | solifenacin succinate | 1 mg/mL | 209529 | 1 | 2021-05-27 |
US Patents and Regulatory Information for VESICARE LS
VESICARE LS is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | VESICARE LS | solifenacin succinate | SUSPENSION;ORAL | 209529-001 | May 26, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VESICARE LS
See the table below for patents covering VESICARE LS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011255951 | Pharmaceutical composition containing solifenacin | ⤷ Start Trial |
| Brazil | 112012029461 | composição farmacêutica contendo solifenacina | ⤷ Start Trial |
| Canada | 2799942 | COMPOSITION PHARMACEUTIQUE CONTENANT DE LA SOLIFENACINE (PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN) | ⤷ Start Trial |
| China | 102905706 | Pharmaceutical composition containing solifenacin | ⤷ Start Trial |
| Cyprus | 1117816 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VESICARE LS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0801067 | 04C0032 | France | ⤷ Start Trial | PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216 |
| 0801067 | SPC/GB04/029 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816 |
| 0801067 | C00801067/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch